PURPOSE: Increased expression and/or activation of epidermal growth factor receptor (EGFR) is associated with tumor progression and poor prognosis in many cancers, including head and neck squamous cell carcinoma (HNSCC). Src family kinases, including c-Src, mediate a variety of intracellular or extracellular signals that contribute to tumor formation and progression. This study was undertaken to elucidate the role of c-Src in the growth and invasion of HNSCC and to determine the effects of combined targeting of EGFR and Src kinases in HNSCC cell lines. EXPERIMENTAL DESIGN: HNSCC cells were engineered to stably express a dominant-active form of c-Src and investigated in cell growth and invasion assays. The biochemical effects of combined treatment with the Src inhibitor AZD0530, a potent, orally active Src inhibitor with Bcr/Abl activity, and the EGFR kinase inhibitor gefitinib were examined, as well as the consequences of dual Src/EGFR targeting on the growth and invasion of a panel of HNSCC cell lines. RESULTS: HNSCC cells expressing dominant-active c-Src showed increased growth and invasion compared with vector-transfected controls. Combined treatment with AZD0530 and gefitinib resulted in greater inhibition of HNSCC cell growth and invasion compared with either agent alone. CONCLUSIONS: These results suggest that increased expression and activation of c-Src promotes HNSCC progression where combined targeting of EGFR and c-Src may be an efficacious treatment approach.
PURPOSE: Increased expression and/or activation of epidermal growth factor receptor (EGFR) is associated with tumor progression and poor prognosis in many cancers, including head and neck squamous cell carcinoma (HNSCC). Src family kinases, including c-Src, mediate a variety of intracellular or extracellular signals that contribute to tumor formation and progression. This study was undertaken to elucidate the role of c-Src in the growth and invasion of HNSCC and to determine the effects of combined targeting of EGFR and Src kinases in HNSCC cell lines. EXPERIMENTAL DESIGN: HNSCC cells were engineered to stably express a dominant-active form of c-Src and investigated in cell growth and invasion assays. The biochemical effects of combined treatment with the Src inhibitor AZD0530, a potent, orally active Src inhibitor with Bcr/Abl activity, and the EGFR kinase inhibitor gefitinib were examined, as well as the consequences of dual Src/EGFR targeting on the growth and invasion of a panel of HNSCC cell lines. RESULTS: HNSCC cells expressing dominant-active c-Src showed increased growth and invasion compared with vector-transfected controls. Combined treatment with AZD0530 and gefitinib resulted in greater inhibition of HNSCC cell growth and invasion compared with either agent alone. CONCLUSIONS: These results suggest that increased expression and activation of c-Src promotes HNSCC progression where combined targeting of EGFR and c-Src may be an efficacious treatment approach.
Authors: C Bénistant; H Chapuis; N Mottet; J Noletti; E Crapez; J P Bali; S Roche Journal: Biochem Biophys Res Commun Date: 2000-07-05 Impact factor: 3.575
Authors: R B Irby; W Mao; D Coppola; J Kang; J M Loubeau; W Trudeau; R Karl; D J Fujita; R Jove; T J Yeatman Journal: Nat Genet Date: 1999-02 Impact factor: 38.330
Authors: Matthew G Fury; Shrujal Baxi; Ronglai Shen; Katherine W Kelly; Brynna L Lipson; Diane Carlson; Hilda Stambuk; Sofia Haque; David G Pfister Journal: Anticancer Res Date: 2011-01 Impact factor: 2.480
Authors: Wei Yang; Quan Cai; Vivian W Y Lui; Patrick A Everley; Jayoung Kim; Neil Bhola; Kelly M Quesnelle; Bruce R Zetter; Hanno Steen; Michael R Freeman; Jennifer R Grandis Journal: J Proteome Res Date: 2010-06-04 Impact factor: 4.466
Authors: Amanda Gatesman Ammer; Laura C Kelley; Karen E Hayes; Jason V Evans; Lesly Ann Lopez-Skinner; Karen H Martin; Barbara Frederick; Brian L Rothschild; David Raben; Paul Elvin; Tim P Green; Scott A Weed Journal: J Cancer Sci Ther Date: 2009-11-30
Authors: Athanassios Argiris; Trevor M Feinstein; Lin Wang; Tianbing Yang; Shruti Agrawal; Leonard J Appleman; Ronald G Stoller; Jennifer R Grandis; Ann Marie Egloff Journal: Invest New Drugs Date: 2011-09-01 Impact factor: 3.850